Journal Article

Artificial Intelligence Evaluation of Stool Quality Guides Management of Hepatic Encephalopathy Using a Smartphone App

Anstey, Jacob, Tiede, David, Kraus, Asaf, Bajaj, Jasmohan S., Mousel, Travis, Puri, Puneet, Simonetto, Douglas A., Davis, Brian C., Fagan, Andrew, Fuchs, Michael, Gallagher, Mary Leslie

2024

Overview

Lactulose-based hepatic encephalopathy treatment requires bowel movements/day titration, which is improved with Bristol stool scale (BSS) incorporation. Dieta app evaluates artificial intelligence (AI)-based BSS (AI-BSS) with stool images. Initially, controls (N = 13) and cirrhosis patients on lactulose/not on lactulose (n = 33) were trained on the app. They entered self-reported BSS (self-BSS) with AI-BSS communicated. Lactulose dose changes were tracked. A subset (n = 12) was retested with AI communication blocked. Most subjects were comfortable with the app. Self/AI-BSS and lactulose dose/AI-BSS correlation increased with app use. AI-BSS communications improved insight into self-BSS over time. Dieta app to gauge stool AI characteristics was acceptable and increased insight into lactulose dose and BSS in cirrhosis.

• Publisher: Wolters Kluwer,Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
• Subject: Adult / Aged / Artificial Intelligence / Communication / Feces - chemistry / Female / Gastrointestinal Agents - administration & dosage / Gastrointestinal Agents - therapeutic use / Hepatic Encephalopathy - therapy / Hepatology / Humans / Irritable bowel syndrome / Lactulose - administration & dosage / Lactulose - therapeutic use / Liver cirrhosis / Liver Cirrhosis - complications / Liver diseases / Male / Middle Aged / Mobile Applications / Patients / Privacy / Self-efficacy / Smartphone / Smartphones